Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 407 of 6351
-
A gentle workout may fight cancer fatigue
Symptom relief Recruiting nowTo conduct a randomized controlled trial (RCT) targeting lung cancer patients with cancer-related fatigue to achieve the following objectives: Objective 1: To investigate whether a low-intensity endurance exercise intervention can effectively improve mitochondrial DNA content, m…
Sponsor: Taipei Medical University • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
New Immune-Calming therapy could slow progressive MS
Disease control Not yet recruitingThe investigators propose to design and conduct a phase IIa clinical trial to treat patients with progressive forms of multiple sclerosis (MS) by vaccination with tolerogenic dendritic cells (tolDC), generated using Good Manufacturing Practices (GMP). Hereby, the investigators wa…
Phase 2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingIn this study it is aimed to analyze the efficacy and safety of Tb-161 PSMA I\&T in the 7.4 GBq activity in a large patient group of Lu-177 PSMA naïve mCRPC patients. 3 cycles of Tb-161 PSMA will be administered with 6 weeks periods. After each cycle a triple bed quantitative sin…
Phase 2 • Sponsor: Ankara University • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
Hope for Huntington's: new drug aims to slow decline in major trial
Disease control Recruiting nowThe goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall w…
Phase 3 • Sponsor: Prilenia • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could less radiation be enough for some lymphoma patients?
Disease control Recruiting nowThis study is designed to evaluate the efficacy and safety of reduced-intensity radiotherapy for stage I/II low-risk nasal-type NK/T-cell lymphoma that has achieved complete remission after chemotherapy.
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New cream targets skin lymphoma without steroids
Disease control Not yet recruitingBackground: CTCL is a rare type of non-Hodgkin lymphoma that primarily affects the skin, causing red patches, plaques, and severe itching. Currently, topical corticosteroids are commonly used for early-stage disease, but long-term application can cause significant skin side effe…
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Herbal formula aims to stop bladder Cancer's return
Disease control Recruiting nowThis study is a phase IIA, single-site, randomized, controlled, open-label clinical trial evaluating the safety and efficacy of the LCS103 oral herbal formula for the secondary prevention of NMIBC. The study will include 60 participants randomized 1:1 to either the investigationa…
Sponsor: LifeBiotic Medical Research Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Robotic leg trainer put to the test for restoring gait after paralysis and surgery
Disease control Not yet recruitingThe goal of this clinical trial is to learn if robot-assisted lower-limb strength and gait training can improve safety, feasibility, and functional recovery in adults aged 18-60 years with lower-limb motor dysfunction due to stroke, incomplete spinal cord injury, or persistent ga…
Sponsor: Bangladesh Medical University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New injection aims to shed pounds: phase 2 trial launches
Disease control Recruiting nowThis study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet c…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Heart-Thickening drug trial aims to reverse damage
Disease control Not yet recruitingThe goal of this trial is to learn whether adding the blood pressure medication baxdrostat (Baxfendy) to standard-of-care medical therapies will beneficially change the heart structure and function of adults who have high blood pressure, thickened left heart walls, and are at ris…
Phase 3 • Sponsor: Subodh Verma • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Which nerve block eases Children's heart surgery pain better?
Symptom relief By invitation onlyPostoperative pain management is an essential component of perioperative care in pediatric congenital cardiac surgery. Regional anesthesia techniques, including the erector spinae plane block (ESPB) and modified pectoral fascial plane block (M-PFPB), are increasingly used as part…
Sponsor: Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Could a One-Time treatment give kidney cancer patients a year off drugs?
Disease control Not yet recruitingThis is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response/stable disease after at least 6 months of immune checkp…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tame liver side effects of cancer immunotherapy
Disease control Not yet recruitingThis phase II study evaluates whether early treatment with mycophenolate mofetil (MMF) plus prednisone improves liver inflammation caused by immune checkpoint inhibitors. The study includes patients who develop moderate to severe immune-related hepatitis after receiving PD-(L)1 o…
Phase 2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
PET scan could predict best drug sequence for advanced breast cancer
Disease control Stopped earlyZEPHIR-02 is a multicentre, open-label phase II study that will enroll subjects with HER2-positive advanced/metastatic breast cancer (mBC) who have experienced disease progression under trastuzumab deruxtecan (T-DXd) in the metastatic setting. All subjects will undergo baseline …
Phase 2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug duo takes on recurrent brain cancer
Disease control Recruiting nowThe primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.
Phase 2 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for rare leukemia: drug cocktail shows promise
Disease control Not yet recruitingAcute leukemia of ambiguous lineage (ALAL), which refers to acute leukemia without definite evidence indicating cell differentiation along a specific lineage, mainly encompasses two major categories: acute undifferentiated leukemia (AUL) lacking the expression of lineage-specific…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Real-World check: targeted drug MIRV tested against tough ovarian cancer
Disease control Not yet recruitingEpithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancers, is a lethal disease with 3,221 new cases reported in 2021 in Korea. The purpose of this study is to evaluate the adverse events and change in disease activity of mirvetuximab soravtansine-gyn…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Major trial asks: is radiation necessary for Low-Risk breast lesions?
Knowledge-focused Not yet recruitingNRG-CC016 is being done to determine if omission of radiation therapy (RT) for patients with biosignature Low Risk (DCISionRT score less than 2.8) DCIS yields no clinically meaningful increase ipsilateral breast recurrence (IBR) compared to those treated with RT (Cohort A).
Phase 3 • Sponsor: NRG Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
New PET tracer aims to spot hidden cancer spread in the abdomen
Diagnosis Recruiting nowThis is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of \[68Ga\]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial…
Phase 2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Triple-Drug attack aims to shrink cervical cancer tumors
Disease control Not yet recruitingThis study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.
Phase 2 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC